ProQR Therapeutics NV (NASDAQ:PRQR) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 985,408 shares, an increase of 60.6% from the October 15th total of 613,551 shares. Based on an average daily volume of 254,800 shares, the days-to-cover ratio is presently 3.9 days. Approximately 3.7% of the shares of the stock are short sold.

Shares of NASDAQ PRQR opened at $19.08 on Friday. ProQR Therapeutics has a 52-week low of $2.75 and a 52-week high of $24.00. The stock has a market capitalization of $774.80 million, a PE ratio of -9.84 and a beta of 0.54. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.26.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.10. Research analysts predict that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in shares of ProQR Therapeutics by 0.6% in the third quarter. Jennison Associates LLC now owns 2,998,094 shares of the biopharmaceutical company’s stock worth $58,013,000 after buying an additional 16,889 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of ProQR Therapeutics by 519.0% in the first quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 28,025 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its stake in shares of ProQR Therapeutics by 50.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 30,000 shares in the last quarter. Ardsley Advisory Partners purchased a new position in shares of ProQR Therapeutics in the second quarter worth about $365,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of ProQR Therapeutics in the second quarter worth about $604,000. 28.55% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on PRQR. BidaskClub lowered shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research upgraded shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of ProQR Therapeutics in a research report on Tuesday, October 30th. Evercore ISI began coverage on shares of ProQR Therapeutics in a research report on Tuesday, September 18th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, ValuEngine upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 6th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. ProQR Therapeutics currently has a consensus rating of “Buy” and an average target price of $18.00.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://theolympiareport.com/2018/11/11/proqr-therapeutics-nv-prqr-sees-large-increase-in-short-interest.html.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Story: Price to Earnings Ratio (PE)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.